LifeMD, Inc. (NASDAQ:LFMD) Receives $7.57 Consensus Price Target from Analysts

LifeMD, Inc. (NASDAQ:LFMD) has received an average rating of “Moderate Buy” from the ten research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $7.5714.

A number of equities analysts have recently weighed in on LFMD shares. Weiss Ratings reiterated a “sell (d)” rating on shares of LifeMD in a research note on Tuesday, August 4th. Lake Street Capital set a $5.00 price objective on LifeMD in a report on Thursday, August 6th. Zacks Research upgraded LifeMD from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, UBS Group reissued a “buy” rating on shares of LifeMD in a report on Wednesday, May 27th.

LifeMD Price Performance

NASDAQ:LFMD opened at $3.44 on Tuesday. The company has a market cap of $165.81 million, a P/E ratio of -68.79 and a beta of 2.04. The firm’s fifty day moving average price is $3.64 and its two-hundred day moving average price is $3.99. LifeMD has a one year low of $2.56 and a one year high of $7.32.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The company had revenue of $47.28 million during the quarter, compared to the consensus estimate of $49.16 million. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. As a group, equities research analysts expect that LifeMD will post -0.46 earnings per share for the current year.

Institutional Trading of LifeMD

Several hedge funds and other institutional investors have recently bought and sold shares of LFMD. Walleye Capital LLC acquired a new stake in shares of LifeMD in the second quarter valued at approximately $1,338,000. Russell Investments Group Ltd. boosted its stake in shares of LifeMD by 5,801.2% in the second quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company’s stock valued at $1,300,000 after buying an additional 309,436 shares during the period. Penn Capital Management Company LLC acquired a new stake in LifeMD during the second quarter worth approximately $926,000. Whetstone Capital Advisors LLC grew its position in LifeMD by 89.6% during the fourth quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock worth $2,397,000 after buying an additional 332,269 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. bought a new position in LifeMD during the 4th quarter worth $2,344,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.